China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Down 37.4% in June

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) was the recipient of a significant drop in short interest during the month of June. As of June 30th, there was short interest totaling 45,019 shares, a drop of 37.4% from the June 15th total of 71,896 shares. Based on an average daily volume of 50,754 shares, the short-interest ratio is presently 0.9 days. Currently, 0.1% of the shares of the company are sold short.

China SXT Pharmaceuticals Stock Down 4.7%

NASDAQ:SXTC opened at $2.45 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.76 and a current ratio of 7.94. China SXT Pharmaceuticals has a 52 week low of $1.25 and a 52 week high of $1,046.98. The stock’s 50-day moving average price is $2.04 and its 200-day moving average price is $18.54.

China SXT Pharmaceuticals (NASDAQ:SXTC) last released its quarterly earnings results on Wednesday, July 1st. The company reported ($0.07) earnings per share for the quarter. The company had revenue of $0.26 million during the quarter.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Citadel Advisors LLC purchased a new position in shares of China SXT Pharmaceuticals during the 3rd quarter valued at approximately $78,000. Virtu Financial LLC increased its holdings in China SXT Pharmaceuticals by 107.5% in the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock worth $46,000 after acquiring an additional 15,013 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in China SXT Pharmaceuticals in the 4th quarter worth $36,000. 5.02% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, July 10th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.